# Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

> **NCT01222572** · PHASE1,PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 1 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Lung Cancer
- NSCLC

## Interventions

- **RADIATION:** Stereotactic boost
- **RADIATION:** Conventional RT
- **DRUG:** Etoposide
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01222572
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2012-03
- **Final completion:** 2012-10
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow accrual due to restrictive eligibility criteria
- **Last updated:** 2015-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01222572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01222572, "Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01222572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*